| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 14 | 2025 | 509 | 3.930 |
Why?
|
| Liver Neoplasms | 21 | 2024 | 1300 | 2.930 |
Why?
|
| Hepatoblastoma | 13 | 2024 | 178 | 2.530 |
Why?
|
| Natural Killer T-Cells | 7 | 2025 | 77 | 2.330 |
Why?
|
| Glypicans | 4 | 2024 | 39 | 2.190 |
Why?
|
| Interleukin-15 | 5 | 2025 | 93 | 2.030 |
Why?
|
| Immunotherapy, Adoptive | 12 | 2025 | 789 | 1.970 |
Why?
|
| Carcinoma, Hepatocellular | 9 | 2024 | 927 | 1.760 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2023 | 478 | 1.310 |
Why?
|
| T-Lymphocytes | 8 | 2024 | 1676 | 1.220 |
Why?
|
| Bone Neoplasms | 2 | 2023 | 426 | 1.170 |
Why?
|
| Synthetic Biology | 1 | 2025 | 14 | 0.980 |
Why?
|
| Receptors, Antigen | 3 | 2016 | 34 | 0.950 |
Why?
|
| Neoplasms | 5 | 2024 | 2746 | 0.890 |
Why?
|
| Gangliosides | 4 | 2025 | 64 | 0.860 |
Why?
|
| Immunotherapy | 4 | 2017 | 654 | 0.840 |
Why?
|
| Osteosarcoma | 1 | 2023 | 257 | 0.730 |
Why?
|
| DNA | 1 | 2025 | 1591 | 0.660 |
Why?
|
| Interleukins | 1 | 2020 | 116 | 0.650 |
Why?
|
| CD28 Antigens | 2 | 2016 | 78 | 0.640 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 101 | 0.600 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2016 | 25 | 0.540 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 104 | 0.530 |
Why?
|
| Child | 24 | 2024 | 24086 | 0.530 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 101 | 0.520 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 498 | 0.520 |
Why?
|
| Lymphoma, B-Cell | 2 | 2016 | 135 | 0.520 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 187 | 0.520 |
Why?
|
| Osteopetrosis | 1 | 2015 | 13 | 0.510 |
Why?
|
| Diphosphonates | 1 | 2015 | 38 | 0.500 |
Why?
|
| Health Care Costs | 1 | 2018 | 364 | 0.500 |
Why?
|
| Femoral Fractures | 1 | 2015 | 33 | 0.500 |
Why?
|
| Femur | 1 | 2015 | 63 | 0.500 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2023 | 263 | 0.500 |
Why?
|
| Ambulatory Care | 1 | 2018 | 376 | 0.500 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 769 | 0.490 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 390 | 0.460 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 1015 | 0.440 |
Why?
|
| Child, Preschool | 17 | 2024 | 13794 | 0.420 |
Why?
|
| Humans | 43 | 2025 | 122633 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1229 | 0.410 |
Why?
|
| Lymphocyte Activation | 5 | 2020 | 678 | 0.410 |
Why?
|
| Cancer Vaccines | 1 | 2014 | 186 | 0.410 |
Why?
|
| Cell Proliferation | 5 | 2024 | 2306 | 0.360 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2024 | 876 | 0.350 |
Why?
|
| Cytokines | 4 | 2024 | 1280 | 0.350 |
Why?
|
| Adolescent | 16 | 2024 | 18987 | 0.350 |
Why?
|
| Mice | 11 | 2024 | 17430 | 0.330 |
Why?
|
| Male | 21 | 2024 | 59714 | 0.300 |
Why?
|
| Incidence | 3 | 2024 | 3040 | 0.280 |
Why?
|
| Animals | 12 | 2024 | 33618 | 0.280 |
Why?
|
| Liver Transplantation | 6 | 2020 | 1007 | 0.260 |
Why?
|
| Survival Rate | 4 | 2024 | 1992 | 0.260 |
Why?
|
| Mice, Inbred NOD | 4 | 2020 | 285 | 0.260 |
Why?
|
| Female | 19 | 2024 | 65117 | 0.260 |
Why?
|
| Neutropenia | 3 | 2024 | 202 | 0.250 |
Why?
|
| Mice, SCID | 4 | 2020 | 571 | 0.250 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2024 | 21 | 0.230 |
Why?
|
| Mutagenesis, Insertional | 1 | 2025 | 147 | 0.230 |
Why?
|
| Adenosine Deaminase | 1 | 2024 | 74 | 0.230 |
Why?
|
| Infant | 11 | 2024 | 12272 | 0.230 |
Why?
|
| Genetic Engineering | 1 | 2025 | 161 | 0.230 |
Why?
|
| Young Adult | 7 | 2024 | 8817 | 0.230 |
Why?
|
| Mutagenesis | 1 | 2025 | 347 | 0.220 |
Why?
|
| SEER Program | 2 | 2022 | 193 | 0.220 |
Why?
|
| Vincristine | 2 | 2024 | 195 | 0.220 |
Why?
|
| Sequence Deletion | 1 | 2025 | 527 | 0.210 |
Why?
|
| Prognosis | 7 | 2024 | 4488 | 0.200 |
Why?
|
| Cohort Studies | 2 | 2024 | 4686 | 0.200 |
Why?
|
| Lymphocyte Depletion | 2 | 2024 | 123 | 0.200 |
Why?
|
| Adult | 7 | 2024 | 28881 | 0.190 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 18 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 1063 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 1 | 2025 | 1584 | 0.190 |
Why?
|
| Lymphoma | 1 | 2024 | 321 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 1085 | 0.180 |
Why?
|
| Leukemia | 1 | 2024 | 376 | 0.180 |
Why?
|
| Treatment Outcome | 8 | 2023 | 12055 | 0.180 |
Why?
|
| Vidarabine | 1 | 2020 | 79 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 29 | 0.180 |
Why?
|
| Middle Aged | 4 | 2024 | 25849 | 0.170 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 42 | 0.170 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 97 | 0.170 |
Why?
|
| Aicardi Syndrome | 1 | 2019 | 14 | 0.170 |
Why?
|
| Automobiles | 1 | 2019 | 3 | 0.170 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 2019 | 38 | 0.170 |
Why?
|
| Immunity | 1 | 2020 | 183 | 0.170 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 102 | 0.170 |
Why?
|
| Macrophages | 2 | 2014 | 607 | 0.160 |
Why?
|
| Escherichia coli | 1 | 2025 | 980 | 0.160 |
Why?
|
| United States | 3 | 2024 | 10559 | 0.160 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 272 | 0.160 |
Why?
|
| Vocal Cord Paralysis | 1 | 2020 | 68 | 0.160 |
Why?
|
| Embolization, Therapeutic | 1 | 2021 | 225 | 0.160 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 13 | 0.160 |
Why?
|
| Transplantation Conditioning | 2 | 2017 | 323 | 0.160 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 1297 | 0.160 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 420 | 0.150 |
Why?
|
| Aged | 3 | 2024 | 18982 | 0.150 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2018 | 14 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2018 | 1466 | 0.150 |
Why?
|
| Registries | 1 | 2024 | 1379 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2020 | 305 | 0.140 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2018 | 95 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 318 | 0.140 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 114 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2017 | 138 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2017 | 140 | 0.140 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2017 | 43 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2018 | 383 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 62 | 0.140 |
Why?
|
| Myeloid Cells | 1 | 2017 | 98 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1240 | 0.140 |
Why?
|
| Bile Duct Neoplasms | 1 | 2018 | 109 | 0.140 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 107 | 0.140 |
Why?
|
| Acetylation | 1 | 2017 | 166 | 0.130 |
Why?
|
| L-Selectin | 1 | 2016 | 21 | 0.130 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8064 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 712 | 0.130 |
Why?
|
| Transduction, Genetic | 2 | 2014 | 277 | 0.130 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2018 | 223 | 0.130 |
Why?
|
| Apoptosis | 2 | 2020 | 1782 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 151 | 0.130 |
Why?
|
| Cell Polarity | 1 | 2016 | 125 | 0.130 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 88 | 0.130 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 351 | 0.130 |
Why?
|
| Antigens, CD19 | 1 | 2016 | 177 | 0.120 |
Why?
|
| Retrospective Studies | 9 | 2024 | 15916 | 0.120 |
Why?
|
| Liver Diseases | 1 | 2019 | 362 | 0.120 |
Why?
|
| Brain Diseases | 1 | 2018 | 294 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 352 | 0.120 |
Why?
|
| 4-1BB Ligand | 1 | 2014 | 11 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 669 | 0.120 |
Why?
|
| Disease Management | 1 | 2018 | 514 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 5019 | 0.120 |
Why?
|
| Antigens, CD1d | 1 | 2014 | 21 | 0.120 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2013 | 2 | 0.110 |
Why?
|
| Retroviridae | 1 | 2014 | 194 | 0.110 |
Why?
|
| Sarcoma | 1 | 2016 | 193 | 0.110 |
Why?
|
| Health Personnel | 1 | 2018 | 500 | 0.110 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 964 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 500 | 0.110 |
Why?
|
| Liver | 2 | 2019 | 1725 | 0.110 |
Why?
|
| Radiography | 1 | 2015 | 815 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2018 | 621 | 0.110 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 1801 | 0.100 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 236 | 0.100 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 3283 | 0.100 |
Why?
|
| Health Status | 1 | 2014 | 373 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 751 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 532 | 0.100 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 648 | 0.100 |
Why?
|
| Risk | 1 | 2013 | 746 | 0.100 |
Why?
|
| Hepatectomy | 2 | 2023 | 108 | 0.100 |
Why?
|
| Parents | 1 | 2018 | 1017 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1114 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 1215 | 0.090 |
Why?
|
| Thrombocytopenia | 2 | 2024 | 229 | 0.090 |
Why?
|
| Graft vs Host Disease | 1 | 2014 | 542 | 0.090 |
Why?
|
| Postoperative Complications | 2 | 2021 | 2996 | 0.080 |
Why?
|
| Pediatrics | 1 | 2018 | 1137 | 0.080 |
Why?
|
| Mutation | 2 | 2022 | 5771 | 0.080 |
Why?
|
| Cell Line | 1 | 2014 | 2774 | 0.080 |
Why?
|
| Phenotype | 1 | 2017 | 4200 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2395 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2018 | 357 | 0.070 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2025 | 57 | 0.060 |
Why?
|
| Inosine | 1 | 2024 | 11 | 0.060 |
Why?
|
| Hydroxamic Acids | 1 | 2024 | 56 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2024 | 74 | 0.060 |
Why?
|
| Margins of Excision | 1 | 2023 | 51 | 0.050 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 14 | 0.050 |
Why?
|
| Kynurenine | 1 | 2023 | 22 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 98 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 326 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2023 | 293 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 333 | 0.040 |
Why?
|
| Hoarseness | 1 | 2020 | 11 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 538 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2020 | 99 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 273 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 210 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2020 | 69 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1418 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2019 | 98 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 614 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 186 | 0.040 |
Why?
|
| Chromosome Banding | 1 | 2017 | 140 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 771 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2017 | 330 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 645 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2017 | 137 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1380 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2017 | 322 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 118 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 602 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 1003 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 354 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2024 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 1577 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 182 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 803 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1238 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 803 | 0.030 |
Why?
|
| Chemokine CCL20 | 1 | 2012 | 16 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2012 | 57 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 95 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 254 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 369 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 865 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 3047 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 6012 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 669 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1872 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 1192 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 1471 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 831 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 3710 | 0.020 |
Why?
|
| Texas | 1 | 2014 | 3541 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 9943 | 0.020 |
Why?
|